Cell-surface and cytokine biomarkers in autoimmune and inflammatory diseases.

[1]  K. Narayan,et al.  The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies , 2005, Journal of Neuroimmunology.

[2]  P. Gregersen,et al.  Peripheral blood gene expression profiling in rheumatoid arthritis , 2005, Genes and Immunity.

[3]  M. Dougados,et al.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[4]  M. Z. Cader,et al.  Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. , 2005, Human molecular genetics.

[5]  A. Rudensky,et al.  A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3 , 2005, Nature Immunology.

[6]  Roland Martin,et al.  Immunology of multiple sclerosis. , 2005, Annual review of immunology.

[7]  A. Saraux,et al.  Rheumatoid factor on a daily basis , 2005, Autoimmunity.

[8]  E. Fox.  Immunopathology of multiple sclerosis , 2004, Neurology.

[9]  M. Kaps,et al.  CD45RA+ ICAM‐3+ lymphocytes in interferon‐β1b‐treated and ‐untreated patients with relapsing–remitting multiple sclerosis , 2004, Acta neurologica Scandinavica.

[10]  B. Bisikirska,et al.  Use of Anti‐CD3 Monoclonal Antibody to Induce Immune Regulation in Type 1 Diabetes , 2004, Annals of the New York Academy of Sciences.

[11]  M. Peterson,et al.  Coordinate overexpression of interferon‐α–induced genes in systemic lupus erythematosus , 2004 .

[12]  P. Gregersen,et al.  The emerging role of interferon in human systemic lupus erythematosus. , 2004, Current opinion in immunology.

[13]  F. Weber,et al.  Interferon beta‐1b modulates serum sVCAM‐1 levels in primary progressive multiple sclerosis , 2004, Acta neurologica Scandinavica.

[14]  D. Isenberg,et al.  Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy , 2004, The Journal of experimental medicine.

[15]  M. Weisman,et al.  Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[16]  W. Weimar,et al.  Differential Effect of Calcineurin Inhibitors, Anti-CD25 Antibodies and Rapamycin on the Induction of FOXP3 in Human T Cells , 2005, Transplantation.

[17]  J. Yazdany,et al.  The role of CD40 ligand in systemic lupus erythematosus , 2004, Lupus.

[18]  C. Weyand,et al.  T-cell regulation in rheumatoid arthritis , 2004, Current opinion in rheumatology.

[19]  K. Matsushima,et al.  Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis , 2003, Journal of the Neurological Sciences.

[20]  G. Firestein,et al.  Measurement of Inflammatory Biomarkers in Synovial Tissue Extracts by Enzyme-Linked Immunosorbent Assay , 2003, Clinical Diagnostic Laboratory Immunology.

[21]  H. Reijonen,et al.  Detection of CD4+ Autoreactive T Cells in T1D Using HLA Class II Tetramers , 2003, Annals of the New York Academy of Sciences.

[22]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[23]  K. Hagihara,et al.  Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[24]  Karin Reiter,et al.  Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[25]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[26]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Isenberg,et al.  An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[28]  F. Sellebjerg,et al.  Selective suppression of chemokine receptor CXCR3 expression by interferon-b1a in multiple sclerosis , 2002, Multiple sclerosis.

[29]  P. Lipsky.  Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity , 2001, Nature Immunology.

[30]  M. Feldmann,et al.  Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. , 2001, Arthritis and rheumatism.

[31]  G. Eisenbarth,et al.  Autoantibodies in human diabetes. , 2001, Current directions in autoimmunity.

[32]  P. Limburg,et al.  Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus , 2001, Annals of the rheumatic diseases.

[33]  J. DiMasi,et al.  Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.

[34]  D. Hedley,et al.  Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. , 2001, Cytometry.

[35]  M. Kaps,et al.  CD45RA+ ICAM‐3+ lymphocytesin cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis , 2000, Acta neurologica Scandinavica.

[36]  T. Kishimoto,et al.  Anti-interleukin 6 receptor antibody treatment in rheumatic disease , 2000, Annals of the rheumatic diseases.

[37]  D. Hafler,et al.  Multiple differences in gene expression in regulatory Valpha 24Jalpha Q T cells from identical twins discordant for type I diabetes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Colvin,et al.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand , 2000, Nature Medicine.

[39]  P. Taylor,et al.  Anti-cytokine therapy for rheumatoid arthritis. , 2000, Annual review of medicine.

[40]  P. Marrack,et al.  Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  L. Rassenti,et al.  The soluble CD40 ligand sCD154 in systemic lupus erythematosus. , 1999, The Journal of clinical investigation.

[42]  R. Vakkalanka,et al.  Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. , 1999, Arthritis and rheumatism.

[43]  K. Davies,et al.  Peripheral blood lymphocytes in SLE--hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. , 1998, Journal of autoimmunity.

[44]  M. Feldmann,et al.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[45]  M. Abrahamowicz,et al.  Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? , 1996, The Journal of rheumatology.

[46]  J. Ceuppens,et al.  CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model , 1996, Immunological reviews.

[47]  M. Crow,et al.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. , 1996, The Journal of clinical investigation.

[48]  R. Ramsey‐Goldman,et al.  Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. , 1996, The Journal of clinical investigation.

[49]  M. Abrahamowicz,et al.  Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. , 1996, Arthritis and rheumatism.

[50]  D. Lewis,et al.  The Human gp39 Promoter , 1995, The Journal of Biological Chemistry.

[51]  R. Maini,et al.  Anti-cytokine therapy in rheumatoid arthritis. , 1995, Bailliere's clinical rheumatology.

[52]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[53]  W. Brück,et al.  Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells , 1995, Journal of Neuroimmunology.

[54]  P. Dore‐Duffy,et al.  Expression of immunologically relevant endothelial cell activation antigens on isolated central neurvous system microvessels from patients with multiple sclerosis , 1994, Annals of neurology.

[55]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[56]  J. Clough,et al.  Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment. , 1991, Seminars in arthritis and rheumatism.

[57]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[58]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[59]  A. Thatayatikom,et al.  Rituximab: a promising therapy in systemic lupus erythematosus. , 2006, Autoimmunity reviews.

[60]  P. Lipsky.  Integrating biologic therapy into the comprehensive care of patients with rheumatoid arthritis. , 2005, The Journal of rheumatology. Supplement.

[61]  M. Leandro,et al.  B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. , 2005, Current directions in autoimmunity.

[62]  M. Herrath.  Pathogenesis of type 1 diabetes: a viewpoint. , 2004 .

[63]  G. Eisenbarth.  Type 1 diabetes: molecular, cellular and clinical immunology. , 2004, Advances in experimental medicine and biology.

[64]  L. Lesko,et al.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.

[65]  H. Bootsma,et al.  Anti-DNA antibodies as early predictor for disease exacerbations in SLE , 1998, Clinical reviews in allergy & immunology.